Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

26
Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014

Transcript of Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Page 1: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Residents’ Journal ClubGiao Q. Phan, M.D.September 4, 2014

Page 2: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Melanoma

• Having metastases to regional nodes is the most important prognostic indicator in early-stage melanoma.

• Elective (complete) node dissection was previously routinely used to stage (& possibly improve survival)

Ove

rall

Su

rviv

al

Years

Veronesi – NEJM (1977)

•553 Pts. with stage I-II limb 1 randomized (1967-1974):

Elective node dissection Observation Dissection if

develops palpable mets

Page 3: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival: All stages

Balch et al. JCO 2001;19:3635-48

5-Year Survival Stage I = ~ 94%Stage II = ~ 68%Stage III = ~ 45%Stage IV = ~ 10%

Page 4: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Early days of sentinel LN biopsy

• Described by UCLA surgical oncology group • Radioactive colloid gold 198Au lymphoscintigraphy

Elective LN dissection as “gold standard”

Holmes (UCLA) – Ann Surg (1977)•57 Pts. with injected with radioactive colloid gold

Elective node dissection 17 found to have LN mets

LN mets occur only at area seen by colloid gold

Page 5: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

MSLT-1: Multicenter Selective Lymphadenectomy Trial

• To study the usefulness of SLNB in identifying pts with clinically occult metastases

• To evaluate the clinical effect of immediate complete lymphadenectomy

• 1269 Melanoma pts. with Breslow depth 1.2 mm - 3.5 mm enrolled from 1994 to 2002

Page 6: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Methods• Randomize 60:40 WLE & SLNB

Node dissection immediately if SLNs were (+) for mets

WLE & post-op observation Node dissection if nodal recurrence found later

• Primary endpoint Melanoma-specific survival (MSS): Survival until death from

melanoma

• Secondary endpoints Disease-free survival (DFS): Time until recurrence MSS and DFS: (+)SLN mets vs. (-)SLN mets MSS and DFS: (+)LN mets vs. (-)LN mets

• Stratified for: Breslow thickness, site of primary

Page 7: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Results: Recurrences

P <0.001

Page 8: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival: SLN+ vs. SLN-

SLN(-)

SLN(+)

Disease-Free Survival Melanoma-Specific Survival

P < 0.001 P < 0.001

Page 9: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival: SLNB vs. Observation

Disease-Free Survival Melanoma-Specific Survival

ObsrvSLNB

P = 0.009 P = 0.58

Page 10: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival: Pts without nodal mets

Mel

ano

ma-

Sp

ecif

ic S

urv

ival

(%

)

ObservationSLNB

Page 11: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival: Pts with nodal mets

Mel

ano

ma-

Sp

ecif

ic S

urv

ival

(%)

1: +SLN immed dissn2: Any node mets (1+4)3: Obs node mets dissn4: False (-)SLN node mets

Page 12: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Summary

• SLNB with “immediate” node dissection if SLN+ improves disease-free survival compared to observation with “delayed” dissection when clinically detected.

5-year DFS: 78% vs. 73%; P = 0.009

• SLNB does not improve melanoma-specific survival (i.e., overall survival) compared to observation w/ “delayed” dissection.

5-year MSS: 87% vs. 87%

• SLN+ pts. have worse prognosis than SLN- pts.

5-year DFS: 53% vs. 83%

5-year MSS: 72% vs. 90%

Page 13: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Summary

• ~16% patients with Breslow-depth 1.2mm to 3.5m had nodal metastases during mean follow-up of 5 years (both arms).

• Pts with nodal mets: SLNB pts. had less tumor burden (+1.4 LNs) compared to Obs pts (+3.3 LNs) progression with delay

• Pts with nodal mets: 5-year MSS higher with SLNB vs. Obs.

72% vs. 52%; P = 0.0004

Sub-group analysis; unplanned comparison

Page 14: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Their conclusion (& limitations)

• SLNB has staging and prognostic value in patients with intermediate-thickness melanoma and, coupled with immediate complete lymphadenectomy, improves survival among patients with tumor positive SLN.

Unplanned subgroup analysis

Ascertainment bias/selection bias, i.e., pts known to have +SLN may have been treated/evaluated differently

Page 15: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

• 10-year follow-up of prior data• New data on 314 pts. with >3.5 mm Breslow-depth

Page 16: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival (10-yrs): SLNB vs. Obs: 1.2-3.5mm

Disease-Free Survival Melanoma-Specific Survival

P = 0.01

ObsrvSLNB

P = 0.18

Page 17: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival (10-yrs): SLNB vs. Obs: >3.5mm

Disease-Free Survival Melanoma-Specific Survival

P = 0.03

ObsrvSLNB

P = 0.56

Page 18: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Survival (10-yrs): Prognostic Indicators

Page 19: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

10-yrs incidence node mets: 1.2 -3.5mm

Page 20: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

10-yrs incidence node mets: >3.5mm

Page 21: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

10-yr MSS: Subgroup analyses: 1.2-3.5mm

P < 0.001

P < 0.006

Page 22: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

10-yr MSS: Subgroup analyses: >3.5mm

P = 0.004

P = NS !

P = 0.09

Page 23: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Summary

• No major changes in findings compared to earlier report

• SLNB with “immediate” node dissection if SLN+ improves disease-free survival compared to observation with “delayed” dissection when clinically detected SLNB--but does not improve melanoma-specific survival (i.e., overall survival) compared to observation w/ “delayed” dissection.

• ~20% intermediate-thickness melanoma develop nodal mets

• ~42% thick melanoma develop nodal mets

• The majority of recurrences happen within the first 5 years

[Closer follow-up &/or scans for high-risk patients within the 1st five years]

Page 24: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Their conclusion (& limitations)• “Biopsy-based staging of intermediate-thickness or thick melanoma provides important prognostic information & identifies patients with

nodal metastases who may benefit from immediate complete lymphadenectomy.”• “Biopsy-based management prolongs DFS for all and prolongs MSS for patients with nodal metastases from intermediate-thickness

melanomas.”

Unplanned subgroup analysis

“A separate analysis of pts. with node+ disease is justified by the obvious biologic rationale (i.e., only patients with nodal disease can benefit from nodal intervention)”.

Latent-group analysis (stats method) was used to correct ascertainment bias.

Page 25: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

PROs• The best prognostic indicator• Simple procedure, minimal side effects• Important for entry into adjuvant clinical trials• Personalization of follow-up schedule depending on risks• Early surgery/close follow-up can prevent bulky recurrence &

subsequent difficult surgery

CONS• Costs: $10K - $15K (surgeon, OR, nuclear medicine, etc.)

• Diagnostic, not therapeutic

• Lack of effective adjuvant therapy despite knowing pt. has higher recurrence risks – psychological impact on patient

Interferon alpha-2B (regular & pegylated) is the ONLY drug FDA-approved for adjuvant tx: Increases disease-free survival but not overall survival; 1-year of tx; many sx’s

Need more clinical trials for this!!!!

Page 26: Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.

Next step: MSLT-2

• Since the majority of completion lymphadenectomies for +SLN are negative for further LN mets, is completion lymphadenectomy necessary?

• Randomize“Standard” therary: Completion node dissection

Close observation & followup (w/ U/S, P.E.)

• Follow for MSS and DFS

• Trial in follow-up period

• Any guess????

• In the meantime: ASCO/SSO consensus: Completion node dissection is standard & should be discussed with patient